333 Burnet Avenue
Cincinnati, OH 45229
Moving Scientific Discoveries in Gene and Cell Therapy to Clinical Report Trials
Cincinnati Children’s Translational Core Laboratory is actively involved in moving cell and gene therapies into clinical trials. The Laboratory has continued to support physicians initiating novel clinical trials including providing manufacturing and testing for a gene therapy trial to treat sickle cell anemia and other hemoglobinopathies, Investigational New Drug submission for a trial to treat a rare pediatric lung disease, patient safety testing for treatment of inherited diseases, and support of multiple trials for CAR-T cancer immunotherapy. Dater Foundation support has specifically enabled Cincinnati Children’s Translational Core Laboratory to maintain facilities and practices compliant with the increasing regulatory demands placed on early phase cell and gene therapy trials. With over 1,000 research faculty members and more than 2,500 publications each year, research conducted by Cincinnati Children’s serves as one of the nation’s most significant sources of pediatric scientific discovery and innovation.
Note: This grant is part of a five-year, $250,000 commitment. The Dater Foundation has made similar commitments for two decades.